Transient left ventricular clot in COVID-19-related myocarditis is associated with hypereosinophilic syndrome: a case report

Int J Cardiovasc Imaging. 2021 Nov;37(11):3279-3283. doi: 10.1007/s10554-021-02317-w. Epub 2021 Jun 23.

Abstract

Frequent clinical presentations have been reported in patients with Coronavirus disease 2019 (COVID-19). It may be associated with multi-organ and cardiovascular involvements such as myocarditis and clot formation. Hypereosinophilic syndrome (HES) is a rare disease diagnosed with idiopathic eosinophilia and organ involvement. Here, we report a patient with COVID-19 who presented with clot formation and myocarditis. One month after discharge, regarding persistent peripheral/bone marrow hypereosinophilia and clot in echocardiography, fluorescent in situ hybridization (FISH) analysis was done that showed FIP1L1-CHIC2 fusion (PDGFRɑ rearrangement) in 18% of scored cells and PDGFRβ rearrangement in 12% of scored cells, which confirmed HES diagnosis. Clot formation may be a late manifestation of COVID-19 or myocarditis due to COVID-19, or the first manifestation of HES that COVID-19 might provoke in this rare syndrome.

Keywords: COVID-19; Case report; Coronavirus; Hypereosinophilic syndrome; Left ventricular clot.

Publication types

  • Case Reports

MeSH terms

  • COVID-19*
  • Humans
  • Hypereosinophilic Syndrome* / complications
  • Hypereosinophilic Syndrome* / diagnostic imaging
  • Hypereosinophilic Syndrome* / drug therapy
  • In Situ Hybridization, Fluorescence
  • Myocarditis* / diagnostic imaging
  • Myocarditis* / etiology
  • Oncogene Proteins, Fusion / genetics
  • Predictive Value of Tests
  • SARS-CoV-2

Substances

  • Oncogene Proteins, Fusion